Statement of Stockholders' Equity (Unaudited) - USD ($)	Over-Allotment Option [Member] Preferred Stock [Member] Series C Preferred Stock [Member]	Over-Allotment Option [Member] Preferred Stock [Member]	Over-Allotment Option [Member] Common Stock [Member]	Over-Allotment Option [Member] Additional Paid-in Capital [Member]	Over-Allotment Option [Member] Retained Earnings [Member]	Over-Allotment Option [Member] AOCI Attributable to Parent [Member]	Over-Allotment Option [Member]	Consulting Agreement One [Member] Preferred Stock [Member] Series C Preferred Stock [Member]	Consulting Agreement One [Member] Preferred Stock [Member]	Consulting Agreement One [Member] Common Stock [Member]	Consulting Agreement One [Member] Additional Paid-in Capital [Member]	Consulting Agreement One [Member] Retained Earnings [Member]	Consulting Agreement One [Member] AOCI Attributable to Parent [Member]	Consulting Agreement One [Member]	Consulting Agreement Two [Member] Preferred Stock [Member] Series C Preferred Stock [Member]	Consulting Agreement Two [Member] Preferred Stock [Member]	Consulting Agreement Two [Member] Common Stock [Member]	Consulting Agreement Two [Member] Additional Paid-in Capital [Member]	Consulting Agreement Two [Member] Retained Earnings [Member]	Consulting Agreement Two [Member] AOCI Attributable to Parent [Member]	Consulting Agreement Two [Member]	Private Placement [Member] Preferred Stock [Member] Series C Preferred Stock [Member]	Private Placement [Member] Preferred Stock [Member]	Private Placement [Member] Common Stock [Member]	Private Placement [Member] Additional Paid-in Capital [Member]	Private Placement [Member] Retained Earnings [Member]	Private Placement [Member] AOCI Attributable to Parent [Member]	Private Placement [Member]	Helomics Holding Corp. [Member] Preferred Stock [Member] Series C Preferred Stock [Member]	Helomics Holding Corp. [Member] Preferred Stock [Member]	Helomics Holding Corp. [Member] Common Stock [Member]	Helomics Holding Corp. [Member] Additional Paid-in Capital [Member]	Helomics Holding Corp. [Member] Retained Earnings [Member]	Helomics Holding Corp. [Member] AOCI Attributable to Parent [Member]	Helomics Holding Corp. [Member]	Investor Relations Consultant [Member] Preferred Stock [Member] Series C Preferred Stock [Member]	Investor Relations Consultant [Member] Preferred Stock [Member]	Investor Relations Consultant [Member] Common Stock [Member]	Investor Relations Consultant [Member] Additional Paid-in Capital [Member]	Investor Relations Consultant [Member] Retained Earnings [Member]	Investor Relations Consultant [Member] AOCI Attributable to Parent [Member]	Investor Relations Consultant [Member]	Series E Warrants [Member] Preferred Stock [Member] Series C Preferred Stock [Member]	Series E Warrants [Member] Preferred Stock [Member]	Series E Warrants [Member] Common Stock [Member]	Series E Warrants [Member] Additional Paid-in Capital [Member]	Series E Warrants [Member] Retained Earnings [Member]	Series E Warrants [Member] AOCI Attributable to Parent [Member]	Series E Warrants [Member]	Preferred Stock [Member] Series C Preferred Stock [Member]	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total
Balance (in shares) at Dec. 31, 2016																																																				4,564,428
Balance at Dec. 31, 2016																																																			$ 792	$ 45,644	$ 47,894,196	$ (47,018,451)	$ 1,501	$ 923,682
Shares issued pursuant to the public offering, net (in shares)			175,000																			1,213,819																														1,750,000
Shares issued pursuant to the public offering, net			$ 1,750	$ 392,000			$ 393,750																$ 12,138		$ 1,201,681			$ 1,213,819																								$ 17,500	3,403,688			3,421,188
Vesting Expense																																																					4,042,256			4,042,256
Reverse shares issued for escrow with GLG Pharma pursuant to the termination agreement (in shares)																																																				(400,000)
Reverse shares issued for escrow with GLG Pharma pursuant to the termination agreement																																																				$ (4,000)				(4,000)
Shares issued for services (in shares)										100,000							43,333																					50,000
Shares issued for services										$ 1,000	$ 219,000			$ 220,000			$ 433	$ 63,699			$ 64,132																	$ 500	$ 78,500			$ 79,000
Unrealized (loss) from marketable securities																																																						(1)	(1,501)	(1,501)
Preferred conversion to common shares pursuant to a private placement agreement (in shares)																																																		(566,000)		660,522
Preferred conversion to common shares pursuant to a private placement agreement																																																			(5,659)	$ 6,604	85,236			86,182
Net loss																																																						(7,746,593)		(7,746,593)
Balance (in shares) at Dec. 31, 2017																																																		(647,819)		(6,943,283)
Balance at Dec. 31, 2017																																																			7,271	$ 69,432	57,380,256	(54,765,045)		2,691,914
Shares issued pursuant to the public offering, net (in shares)			215,247																																																	2,900,000
Shares issued pursuant to the public offering, net			$ 2,153	$ 202,268	$ 1		$ 204,422																																													$ 29,000	2,726,087			2,755,087
Vesting Expense																																																					226,387			226,387
Unrealized (loss) from marketable securities
Preferred conversion to common shares pursuant to a private placement agreement (in shares)																																																		(647,819)		589,747
Preferred conversion to common shares pursuant to a private placement agreement																																																			(6,479)	$ 5,897	582
Net loss																																																						(1,760,022)		(1,760,022)
Investment in subsidiary pursuant to Helomics 20% acquisition (in shares)																															1,100,000
Investment in subsidiary pursuant to Helomics 20% acquisition																															$ 11,000	$ 1,031,250			$ 1,042,250
E warrant exercises pursuant to S-3 public offering at $1.00 exercise price per share (in shares)																																													55,796
E warrant exercises pursuant to S-3 public offering at $1.00 exercise price per share																																													$ 558	$ 55,238			$ 55,796
Balance (in shares) at Mar. 31, 2018																																																				(11,804,073)
Balance at Mar. 31, 2018																																																			$ 792	$ 118,040	$ 61,622,067	$ (56,525,066)		$ 5,215,833